Author(s): ,
Georgi Mihaylov
Clinic of Hematology,Specialized Hospital for Active Treatment of Hematology Diseases AD,Sofia,Bulgaria
Galina Kuchma
Department of Hematology,Regional Clinical Hospital ?1,Orenburg,Russian Federation
Jarmila Obernauerová
Department of Hematology,Regional Hospital Mlada Boleslav,Mlada Boleslav,Czech Republic
Barbara Skopec
Department of Hematology,University Medical Center Ljubljana,Ljubljana,Slovenia
Zuzana Sninska
Department of Hematology and Blood Transfusion,University Hospital St. Cyril and Metod,Bratislava,Slovakia
Nikolay Tzvetkov
Clinic of Hematology,University Multiprofile Hospital for Active Treatment 'Dr. Georgi Stranski' EAD,Pleven,Bulgaria
Daniela Niepel
Medical Department,Amgen CEE Headquarters,Vienna,Austria
Peter ?ernel?
Department of Hematology,University Medical Center Ljubljana,Ljubljana,Slovenia
EHA Learning Center. Mihaylov G. Jun 12, 2015; 100265
Disclosure(s): Specialized Hospital for Active Treatment of Hematology Diseases AD
Clinic of Hematology
Prof. Dr. Georgi Mihaylov
Prof. Dr. Georgi Mihaylov

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.

Discussion Forum (0)
Rate & Comment (0)
Abstract: E1415

Type: Eposter Presentation

The thrombopoietin-receptor agonist romiplostim is indicated for adult splenectomised patients (pts) with ITP who are refractory to other treatments and may be considered as second line treatment for adult non-splenectomised pts where surgery is contra-indicated.

The aim of this ongoing study is to assess the use of romiplostim in clinical practice in Bulgaria, Czech Republic, Slovenia, Slovakia, Romania and Russia.

This international single-arm, non-interventional, multicenter, retrospective and prospective study is enrolling adult pts with ITP, who have received at least one application of romiplostim according to the licensed indication. A period of 6 months prior to romiplostim initiation was documented retrospectively from pt files; the prospective observation period started at the time of romiplostim initiation. The total planned observation period is 2 years. All pts provided written informed consent. Assessed parameters included pt demographics, romiplostim application, dosage, adverse drug reactions (ADRs) and reasons of discontinuations, concomitant ITP therapies, clinically relevant bleeding events, and consumption of resources. Data from a protocol-defined interim analysis (IA) at 1 year of prospective observation are reported here.

66 pts were analyzed for the IA (47% male, median age at romiplostim initiation 48 [range 19-82] years, splenectomized n=27, non-splenectomized n=39). Of these, 58 (88%) completed 1 year of study, 8 (12%) discontinued from the study (adverse drug reactions n=1, administrative decision n=2, lost to follow-up n=5). The median time from ITP diagnosis to romiplostim initiation was 2.89 (0-42) years. 34 pts (51.5%) had received ≥3 prior ITP therapies. During the 6 months before romiplostim initiation the event rate per 100 pt years was 111 (95% CI 75.1, 156.8) for bleeding and 92 (95% CI 73.2, 113.0) for ITP-related hospitalizations. The median platelet count at romiplostim start was 19.0 (range 1-411) x 10^9/L, increasing to 52.0 (range 2-361) x 10^9/L after 1 week and remaining above 50 x 10^9/L for the period until IA data cut-off at 1 year (Figure). During the 1-year observation period for IA, pts received a median romiplostim dose of 2.13 (range 0.1-9.1) µg/kg/week and a median of 31 (range 2-53) injections. The event rate per 100 pt years during the 1-year romiplostim treatment period was 58 (95% CI 39.0, 83.6) for bleeding (no grade 3/4 events) and 94 (95% CI 69.3, 125.4) for ITP-related hospitalizations. 4 pts (6.1%) experienced a total of 11 ADRs, with 2 pts experiencing 2 serious ADRs each (thrombosis, dysphagia, lymphocytosis, leucocytosis). 51 pts (77.3%) were hospitalized for 77 ITP-related events during the 1 year observation period for IA for the following reasons: platelet transfusion (n=5, 9.8%), ITP treatment administration (n=24, 47.1%), bleeding event (n=14, 27.5%), infection-related (n=5, 9.8%), splenectomy (n=7, 13.7%), ADR (n=1, 2.0%), other (n=21, 41.2%).

These interim data show that platelet counts in ITP patients treated with romiplostim in clinical practice increased and were maintained within the desired range of 50-250 x 10^9/L. The bleeding event rate was lower during romiplostim treatment. Romiplostim was generally well tolerated.

Keyword(s): Immune thrombocytopenia (ITP), Thrombocytopenia

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings